GlassScriptPhysician profile
Jack Scariano
NPI 1255333977
$20,774.09
in general payments reported to CMS, 2019-2025
63 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,388 · 2020: $2,481 · 2021: $3,380 · 2022: $3,768 · 2023: $3,405 · 2024: $3,003 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,757.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,372.81 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Neurelis, INC. | $1,974.33 | 2020-2025 | Valtoco |
| Biogen, INC. | $1,849.92 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $1,282.22 | 2019-2025 | Ingrezza |
| Eisai INC. | $941.85 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $832.79 | 2021-2025 | Rytary, Crexont, Lyvispah |
| Kyowa Kirin, INC. | $825.95 | 2019-2025 | Nourianz |
| Celgene Corporation | $762.83 | 2021-2025 | Zeposia |
| Avanir Pharmaceuticals, INC. | $597.92 | 2019-2022 | |
| Lilly USA, LLC | $525.83 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Otsuka America Pharmaceutical, INC. | $510.51 | 2023-2025 | Nuedexta, Rexulti |
| Novartis Pharmaceuticals Corporation | $496.29 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $480.97 | 2019-2025 | Austedo Xr |
| Genzyme Corporation | $457.14 | 2019-2025 | |
| Emd Serono, INC. | $445.65 | 2019-2024 | Mavenclad |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Scariano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.